REGENERX BIOPHARMACEUTICALS, INC.: 10-Q filed 2021-11-15

Name: REGENERX BIOPHARMACEUTICALS, INC.: 10-Q filed 2021-11-15
Creator: REGENERX BIOPHARMACEUTICALS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What REGENERX BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2021-11-15 (fiscal Q3 2021): 34 published measures, 108 facts as tagged in accession 0001104659-21-139207.

This filing

Form: 10-Q (quarterly report)
Filed: 2021-11-15
Fiscal period: fiscal Q3 2021
Accession: 0001104659-21-139207 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All REGENERX BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2021-09-30	1,593,542	USD
At 2020-12-31	551,788	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2021-09-30	3,462,210	USD
At 2020-12-31	3,375,732	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2021-09-30	-1,868,668	USD
At 2021-06-30	-1,553,231	USD
At 2021-03-31	-3,119,842	USD
At 2020-12-31	-2,823,944	USD
At 2020-09-30	-2,983,432	USD
At 2020-06-30	-2,724,819	USD
At 2020-03-31	-2,435,091	USD
At 2019-12-31	-2,340,108	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2021-09-30	1,523,390	USD
At 2020-12-31	427,898	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	-429,845	USD	92
2021-01-01 to 2021-09-30	-1,148,170	USD	273
2021-04-01 to 2021-06-30	-338,633	USD	91
2021-01-01 to 2021-03-31	-379,692	USD	90
2020-07-01 to 2020-09-30	-332,599	USD	92
2020-01-01 to 2020-09-30	-1,155,493	USD	274
2020-04-01 to 2020-06-30	-436,161	USD	91
2020-01-01 to 2020-03-31	-386,733	USD	91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	-698,514	USD	273
2020-01-01 to 2020-09-30	-798,416	USD	274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	19,190	USD	92
2021-01-01 to 2021-09-30	57,571	USD	273
2020-07-01 to 2020-09-30	19,190	USD	92
2020-01-01 to 2020-09-30	57,571	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	1,794,006	USD	273
2020-01-01 to 2020-09-30	297,311	USD	274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2021-09-30	-110,040,128	USD
At 2020-12-31	-108,891,958	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	143,482,596	shares	92
2021-01-01 to 2021-09-30	136,922,152	shares	273
2020-07-01 to 2020-09-30	133,441,788	shares	92
2020-01-01 to 2020-09-30	133,328,778	shares	274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	143,482,596	shares	92
2021-01-01 to 2021-09-30	136,922,152	shares	273
2020-07-01 to 2020-09-30	133,441,788	shares	92
2020-01-01 to 2020-09-30	133,328,778	shares	274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	0	USD/shares	92
2021-01-01 to 2021-09-30	-0.01	USD/shares	273
2020-07-01 to 2020-09-30	0	USD/shares	92
2020-01-01 to 2020-09-30	-0.01	USD/shares	274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	0	USD/shares	92
2021-01-01 to 2021-09-30	-0.01	USD/shares	273
2020-07-01 to 2020-09-30	0	USD/shares	92
2020-01-01 to 2020-09-30	-0.01	USD/shares	274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2021-07-01 to 2021-09-30	USD	92
2021-01-01 to 2021-09-30	USD	273
2020-07-01 to 2020-09-30	USD	92
2020-01-01 to 2020-09-30	USD	274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	309,440	USD	273
2020-01-01 to 2020-09-30	270,258	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	-404,046	USD	92
2021-01-01 to 2021-09-30	-960,909	USD	273
2020-07-01 to 2020-09-30	-280,453	USD	92
2020-01-01 to 2020-09-30	-1,003,835	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2021-09-30	1,549,207	USD
At 2020-12-31	477,807	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	81,313	USD	92
2021-01-01 to 2021-09-30	242,798	USD	273
2020-07-01 to 2020-09-30	52,186	USD	92
2020-01-01 to 2020-09-30	155,424	USD	274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2021-09-30	417,503	USD
At 2020-12-31	399,584	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2021-09-30	63,701	USD
At 2020-12-31	39,320	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	423,236	USD	92
2021-01-01 to 2021-09-30	1,018,480	USD	273
2020-07-01 to 2020-09-30	299,643	USD	92
2020-01-01 to 2020-09-30	1,061,406	USD	274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	5,663	USD	92
2021-01-01 to 2021-09-30	6,638	USD	273
2020-07-01 to 2020-09-30	482	USD	92
2020-01-01 to 2020-09-30	4,433	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2021-09-30	143,549,735	shares
At 2020-12-31	133,441,788	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2021-09-30	1,523,390	USD
At 2020-12-31	427,898	USD
At 2020-09-30	138,811	USD
At 2019-12-31	639,916	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2021-09-30	38,583	USD
At 2020-12-31	68,229	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2021-09-30	38,777	USD
At 2020-12-31	68,599	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2021-09-30	5,752	USD
At 2020-12-31	5,752	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2021-09-30	238,264	USD
At 2020-12-31	208,857	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2021-09-30	25,817	USD
At 2020-12-31	49,909	USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

Period	Value	Unit	Days
At 2021-09-30	76,761	USD
At 2020-12-31	76,761	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	-429,845	USD	92
2021-01-01 to 2021-09-30	-1,148,170	USD	273
2020-07-01 to 2020-09-30	-332,599	USD	92
2020-01-01 to 2020-09-30	-1,155,493	USD	274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	417,573	USD	92
2021-01-01 to 2021-09-30	1,011,842	USD	273
2020-07-01 to 2020-09-30	299,161	USD	92
2020-01-01 to 2020-09-30	1,056,973	USD	274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	-25,799	USD	92
2021-01-01 to 2021-09-30	-187,261	USD	273
2020-07-01 to 2020-09-30	-52,146	USD	92
2020-01-01 to 2020-09-30	-151,658	USD	274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	24,381	USD	273
2020-01-01 to 2020-09-30	-3,693	USD	274

Inspect the source

Entity: REGENERX BIOPHARMACEUTICALS, INC. / CIK 0000707511
Captured: 2026-09-22 19:29 UTC
SEC response SHA-256: ffc4eb5988984f6f0271e31d8cf8024b0343b848cad3a73089a36cab28954e4d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000707511.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))